Anaplastic lymphoma kinase (ALK) fusions have been identified as a distinct molecular subtype and potent therapeutic target in several cancers, such as non-small cell lung cancer (NSCLC), accounting for ~4–6% of lung carcinomas3. The gene discussed is ALK; the disease is non-small cell lung carcinoma.